Stevanato Group S.p.A. $STVN Shares Sold by UBS Group AG

UBS Group AG cut its stake in shares of Stevanato Group S.p.A. (NYSE:STVN) by 47.8% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 158,078 shares of the company’s stock after selling 144,673 shares during the quarter. UBS Group AG owned 0.05% of Stevanato Group worth $3,181,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of STVN. Credit Agricole S A bought a new stake in shares of Stevanato Group during the 3rd quarter worth $9,785,000. Bank of America Corp DE boosted its stake in shares of Stevanato Group by 98.1% during the 3rd quarter. Bank of America Corp DE now owns 430,761 shares of the company’s stock worth $11,092,000 after acquiring an additional 213,340 shares in the last quarter. Integrated Wealth Concepts LLC bought a new stake in shares of Stevanato Group during the 3rd quarter worth $4,155,000. Thrivent Financial for Lutherans boosted its stake in shares of Stevanato Group by 7.1% during the 3rd quarter. Thrivent Financial for Lutherans now owns 2,372,390 shares of the company’s stock worth $61,089,000 after acquiring an additional 156,733 shares in the last quarter. Finally, Cooper Investors PTY Ltd. boosted its stake in shares of Stevanato Group by 17.8% during the 4th quarter. Cooper Investors PTY Ltd. now owns 695,245 shares of the company’s stock worth $13,988,000 after acquiring an additional 104,937 shares in the last quarter.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on the company. Morgan Stanley reduced their price objective on Stevanato Group from $24.00 to $19.00 and set an “equal weight” rating for the company in a research note on Friday, March 6th. Jefferies Financial Group set a $17.50 price objective on Stevanato Group in a research note on Tuesday, February 10th. Citigroup reduced their price objective on Stevanato Group from $32.00 to $26.00 and set a “buy” rating for the company in a research note on Thursday, March 5th. Weiss Ratings lowered Stevanato Group from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Wednesday, March 11th. Finally, KeyCorp reduced their price objective on Stevanato Group from $37.00 to $32.00 and set an “overweight” rating for the company in a research note on Thursday, March 5th. Three equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold”.

Stevanato Group Stock Performance

Shares of Stevanato Group stock opened at €18.12 on Monday. The stock has a market cap of $5.49 billion, a PE ratio of 30.72, a price-to-earnings-growth ratio of 1.66 and a beta of 0.75. The business has a fifty day simple moving average of €15.68 and a 200-day simple moving average of €18.13. The company has a quick ratio of 1.11, a current ratio of 1.63 and a debt-to-equity ratio of 0.21. Stevanato Group S.p.A. has a 12 month low of €12.89 and a 12 month high of €28.00.

Stevanato Group (NYSE:STVN) last issued its earnings results on Friday, May 8th. The company reported €0.11 EPS for the quarter, missing the consensus estimate of €0.12 by (€0.01). The business had revenue of €273.57 million during the quarter. Stevanato Group had a return on equity of 10.27% and a net margin of 11.76%.The firm’s revenue for the quarter was up 6.6% compared to the same quarter last year. During the same period in the previous year, the business posted $0.10 earnings per share. On average, sell-side analysts anticipate that Stevanato Group S.p.A. will post 0.68 EPS for the current fiscal year.

About Stevanato Group

Stevanato Group is a global provider of primary packaging solutions and related services for the pharmaceutical and biotech industries. The company specializes in the design, development and manufacturing of glass drug containers such as vials, cartridges and pre-fillable syringes, as well as advanced inspection systems and assembly equipment. Its integrated offerings cover the entire packaging supply chain, from component production to bespoke filling lines and serialization technology.

In addition to its core glass business, Stevanato Group delivers engineering services and process validation support to pharmaceutical customers.